Environmental or self-antigens and homotypic interactions set off BCR and Toll-like receptor (TLR) signaling, amplifying the reaction of CLL cells to other signals through the microenvironment and increasing the activation of anti-apoptotic and proliferation pathways. Duvelisib was the 2nd PI3K inhibitor authorised with the FDA, also determined by a section https://euripidesu742mue9.blogsmine.com/profile